Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges

被引：8
|
作者：
Ceresoli, Giovanni Luca [1 ]
Bonomi, Maria [1 ]
Sauta, Maria Grazia [1 ]
机构：
[1] Clin Humanitas Gavazzeni, Thorac & GU Oncol Unit, Dept Med Oncol, I-24125 Bergamo, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 07期
关键词：
Malignant pleural mesothelioma; immunotherapy; immune-checkpoint inhibitors; SINGLE-ARM; OPEN-LABEL; TREMELIMUMAB; CISPLATIN; BLOCKADE; PHASE-2; CANCER; SAFETY;
D O I：
10.1080/14737140.2016.1191951
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：673 / 675
页数：3
相关论文
共 50 条
  • [31] LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
    Arimura, Ken
    Hiroshima, Kenzo
    Nagashima, Yoji
    Nakazawa, Tadao
    Ogihara, Akira
    Orimo, Mami
    Sato, Yasuto
    Katsura, Hideki
    Kanzaki, Masato
    Kondo, Mitsuko
    Tagaya, Etsuko
    BMC CANCER, 2023, 23 (01)
  • [32] LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
    Ken Arimura
    Kenzo Hiroshima
    Yoji Nagashima
    Tadao Nakazawa
    Akira Ogihara
    Mami Orimo
    Yasuto Sato
    Hideki Katsura
    Masato Kanzaki
    Mitsuko Kondo
    Etsuko Tagaya
    BMC Cancer, 23
  • [33] Trends and challenges in treatment of malignant pleural mesothelioma
    Tsiouris, Athanasios
    Kourliouros, Antonios
    Smith, E. E. John
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (06) : 312 - 313
  • [34] Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
    Moro, Jacopo
    Sobrero, Simona
    Cartia, Carlotta Francesca
    Ceraolo, Simona
    Rapana, Roberta
    Vaisitti, Federico
    Ganio, Stefano
    Mellone, Federica
    Rudella, Stefano
    Scopis, Federico
    La Paglia, Danilo
    Cacciatore, Carola Crystel
    Ruffini, Enrico
    Leo, Francesco
    DIAGNOSTICS, 2022, 12 (12)
  • [35] Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
    Wadowski, Benjamin
    Bueno, Raphael
    De Rienzo, Assunta
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma
    Rovers, S.
    Merlin, C.
    Fisher, S.
    Nowak, A.
    Pauwels, P.
    Lardon, F.
    Van Meerbeeck, J.
    Smits, E.
    Marcq, E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S325 - S325
  • [37] Malignant pleural mesothelioma immune microenvironment and checkpoint expression before and after systemic cytotoxic treatment
    Zago, G.
    Lunardi, F.
    Calabrese, F.
    Vuljan, S. E.
    Urso, L.
    Frega, S.
    Pavan, A.
    Polo, V.
    Bonanno, L.
    Attili, I.
    Rea, F.
    Conte, P. F.
    Pasello, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data
    Kanayama, Masatoshi
    Manabe, Takehiko
    Yoshimatsu, Katsuma
    Oyama, Rintaro
    Matsumiya, Hiroki
    Mori, Masataka
    Takenaka, Masaru
    Kuroda, Koji
    Tanaka, Fumihiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 705 - 717
  • [39] Immune checkpoint inhibitors in mesothelioma: a turning point
    Ceresoli, Giovanni Luca
    Pasello, Giulia
    LANCET, 2021, 397 (10272): : 348 - 349
  • [40] Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
    Perrino, Matteo
    De Vincenzo, Fabio
    Cordua, Nadia
    Borea, Federica
    Aliprandi, Marta
    Santoro, Armando
    Zucali, Paolo Andrea
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345